Free Submission Public Relations &
Deutsch English


Radius Health to Present at Cowen & Company 33rd Annual Health Care Conference in Boston

Print article Print article
© Marketwire 2013
2013-02-26 18:49:29 -

CAMBRIDGE, MA -- (Marketwire) -- 02/26/13 -- Radius Health, Inc. ("Radius"), a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women's health conditions, announced today that it will present at the 33rd annual Cowen & Company Health Care Conference. Michael Wyzga, President and CEO of Radius Health, is scheduled to present on Monday, March 4, at 3:30 p.m. (EST). A breakout session follows the presentation. Senior Vice President and Chief Financial Officer Nick Harvey and Chief Medical Officer Louis Brenner, MD, will also be in attendance.

Radius will provide an update on the company and its Phase 3 asset, BA058, a novel anabolic, bone-building compound under development as a potential treatment for postmenopausal women with osteoporosis at high risk for fracture. BA058-SC, an injectable form of BA058, is currently in a Phase 3 trial, and BA058-TD, is in a Phase 2 trial studying the efficacy of delivering BA058 via transdermal patch. Radius and 3M Drug Delivery Systems have an exclusive partnership agreement for development and commercialization of BA058-TD.

Cowen & Company Health Care Conference
Monday, March 4
3:30 p.m. EST
Boston Marriott Copley Place
Vineyard Room, 4th Floor
110 Huntington Avenue
Boston, MA 02116

About Radius Health
Radius is a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women's health conditions. Radius is committed to the development of advanced therapeutics for the large and underserved osteoporosis market. The Company's lead product candidate, BA058-SC, is in development to reduce the risk of complications associated with osteoporosis, such as fracture. The company also has a next-generation transdermal patch, BA058-TD, being developed as a short wear-time delivery vehicle intended to improve patient compliance with convenience and ease of use, as well as a product in development to treat symptoms associated with menopause. Learn more by visiting the company's new website at : ..


Dave Connolly
617-374-8800 :

Stacey Falardeau
617-374-8800 : docid: 13990467.nitf -->

Press Information:

Contact Person:

Disclaimer: (c) 2014 Market Wire. All of the press releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Market Wire's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News


Terms & Conditions | Privacy | About us | Contact